MorphoSys Reports (L-MIND) Study Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Shots:
- The (L-MIND) study evaluated Monjuvi + lenalidomide for r/r DLBCL. Tafasitamab is co-marketed by Incyte & MorphoSys under the brand name Monjuvi in the US while Minjuvi in the EU, the UK & Canada
- At the data cutoff of Feb 2022, 34% had undergone treatment for 2yrs. with a median duration of therapy of 4.3yrs., 23 were alive & 13 remained on treatment, incl. 6 were on treatment for 5yrs., CR in 23 patients incl. 4 were refractory to their primary therapy, PR in 4 patients & 2 were still on treatment. The results will be presented at SOHO 2022
- Patients experienced a lower frequency of all-grade & grade ≥3 AEs during monothx. The therapy was approved in the US in combination with lenalidomide for r/r DLBCL & has received CMA in the EU
Ref: MorphoSys | Image: MorphoSys
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
